Education
About Us
Working with TipRanks
Follow Us
Oncopeptides AB (SE:ONCO)
:ONCO
ONCO Stock Chart & Stats
kr4.88
>-kr0.01(-0.39%)
At close: 4:00 PM EST
kr4.88
>-kr0.01(-0.39%)
Day’s Range― - ―
52-Week Rangekr1.04 - kr6.56
Previous CloseN/A
Volume80.98K
Average Volume (3M)2.28M
Market Cap
kr1.18B
Enterprise Valuekr1.37B
Total Cash (Recent Filing)kr70.15M
Total Debt (Recent Filing)kr124.23M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Feb 19, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding258,567,470
10 Day Avg. Volume1,913,694
30 Day Avg. Volume2,284,999
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.78
Price to Sales (P/S)8.20
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncopeptides AB News
ONCO FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest stock price was kr1.04 and its highest was kr6.56 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr1.18B.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Feb 19, 2026 which is in 38 days.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on Nov 05, 2025. The company reported -kr0.27 earnings per share for the quarter, beating the consensus estimate of -kr2.48 by kr2.21.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate is -0.19.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 258,567,470 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.27 in its last earnings report, beating expectations of -kr2.48. Following the earnings report the stock price went down -13.472%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in SE:ONCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncopeptides AB
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Xspray Pharma AB
―
Active Biotech AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---